COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
Due to the COVID-19 public health emergency, the Centers for Medicare & Medicaid Services will apply an automatic extreme and uncontrollable circumstances policy to all clinicians participating as individuals in the Quality Payment Program鈥檚 Merit-based Incentive Payment System for the 2020鈥
The Food and Drug Administration will allow undiluted frozen vials of the Pfizer COVID-19 vaccine to be transported and stored at conventional pharmaceutical freezer temperatures (-13掳F to 5掳F) for up to two weeks as an alternative to its preferred storage at -112 F to -76潞F, the agency announced鈥
The Food and Drug Administration's Office of Minority Health and Health Equity released two videos on COVID-19 vaccines and the importance of communities of color who have been disproportionately impacted by COVID-19 getting vaccinated to protect themselves and loved ones from the virus.
The AHA has received $6 million in grants from the Centers for Disease Control and Prevention to promote clinician and public confidence in COVID-19 vaccines, and help train current and future health care personnel to prevent and control infectious disease.
Data submitted to the Food and Drug Administration confirms that Johnson & Johnson鈥檚 COVID-19 vaccine candidate is safe and effective.
Safety monitoring during the first month of the COVID-19 national vaccination program shows 鈥渞eassuring safety profiles鈥 for the Pfizer and Moderna COVID-19 vaccines, the Centers for Disease Control and Prevention reported.
The Centers for Medicare & Medicaid Services extended until March 22 its guidance limiting the hospital survey process during the COVID-19 public health emergency.
CDC lifts COVID-19 quarantine requirement for fully vaccinated individuals outside health care. Get the latest guidance on quarantine for vaccinated individuals.
A report released by the Centers for Disease Control and Prevention highlights the importance of good fit to maximize mask performance.
The Food and Drug Administration authorized administering the monoclonal antibodies bamlanivimab and etesevimab together to treat patients 12 and older with mild-to-moderate COVID-19 who are at high risk for progressing to severe disease but not hospitalized or on oxygen therapy.